Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
labeled RO7269162 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Participants will receive one oral dose of \[14C\]-labeled RO7269162 on Day 1. |
| Name | Type | Description |
|---|---|---|
| [ 14C]-labeled RO7269162 | DRUG | Participants will receive one oral dose of \[14C\]-labeled RO7269162. |
Inclusion Criteria: * Male participants aged 35 to 64 years of age (inclusive), at screening * Body weight ≥ 50 kg and body mass index within the range 18 to 30 kg/m2 (inclusive), at screening * Male participants who, for 3 months after dosing of \[14C\]-RO7269162, agree to: remain abstinent (refra...
RO7269162 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial that enrolled healthy male participants. The drug is not approved for any indication and remains under investigation.
RO7269162 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational small molecule, which is currently in Phase 1 development.
RO7269162 is in Phase 1 clinical development. A single Phase 1 trial has been completed, involving 8 healthy male participants. The drug is investigational and has not been approved for any use.
RO7269162 has one completed clinical trial, NCT06733298, titled "A Study Investigating [14C]-Labeled RO7269162 in Healthy Male Participants." This Phase 1 study enrolled 8 healthy male volunteers in the Netherlands, with participants aged 35 years and older.
RO7269162 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The only completed trial was a small study in healthy volunteers, and the drug has not progressed to later-stage trials or regulatory approval.